Chanda Sanjay — SEC Form 4 filings
SEC reporting owner CIK 1571820. 7 Form 4 filings on record with FilingPulse; latest filed 2026-03-23.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-03-18 to 2026-03-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 12,208 shares, $13,298 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 5,956 shares @ $1.01 ($6,027) in AN2 Therapeutics, Inc., filed 2026-01-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | Chief Development Officer | 7 | — | 3 legs · 12,208 sh · $13,298 | 13 |
Form 4 filings — Chanda Sanjay
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 66,000 (derivative) · Disposition to issuer (D): 66,000 (derivative) · Grant/award (A): 57,950 (derivative) · Disposition to issuer (D): 57,950 (derivative) · Grant/award (A): 41,665 (derivative) · Disposition to issuer (D): 41,665 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 38,000 @ $0 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 3,295 @ $1.00 · Sale (S): 5,956 @ $1.01 | EDGAR |
| 2025-02-28 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 50,250 @ $0 · Grant/award (A): 100,500 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 2,957 @ $1.34 | EDGAR |
| 2024-03-29 | 4/A | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2024-03-18 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 27,500 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1571820 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →